5326122025-07-012025-09-305326122025-09-305326122025-03-315326122025-04-012025-09-305326122025-07-012025-09-30in-capmkt:OtherExpenses1Member5326122025-07-012025-09-30in-capmkt:OtherExpenses2Member5326122025-04-012025-09-30in-capmkt:OtherExpenses1Member5326122025-04-012025-09-30in-capmkt:OtherExpenses2Member5326122025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15326122025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares532612INDOCONOTLISTEDINE873D01024INDOCO REMEDIES LIMITEDMain BoardEquity2025-04-012026-03-312025-11-062025-10-14INRLakhsQuarterlySecond quarterSingle segmentPharmaceutical2025-11-0610:10:002025-11-0611:25:00trueCash Flow IndirectNot applicable2025-07-012025-09-30UnauditedConsolidated4846700000760000048543000001129900000388200000-64700000103230000024560000032250000019305000004984300000-130000000-5300000-135300000500000-43700000-432000000-921000000000-9210000025800000-66300000-79300000-12800000-53500000-128000001845000002-1-100-1-1 <BR> 1) The unaudited Consolidated Results for the Quarter and Half Year ended 30th September, 2025 have been reviewed by the Audit committee and approved by the Board of Director of the Company at its meeting held on 06th November, 2025. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results. <BR> 2) The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. <BR> 3) The company has only one primary reportable segment of activity, namely, Pharmaceuticals. <BR> <BR> 4) Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: <BR> <BR> Net Sales Qtr ended Qtr ended Qtr ended Half year ended Half year ended Year ended <BR> & Income 30-09-2025 30-06-2025 30-09-2024 30-09-2025 30-09-2024 31-03-2025 <BR> from Operations (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) <BR> <BR> India 30,370 27,783 29,017 58,153 54,692 1,09,039 <BR> Outside India 16,813 15,303 14,049 32,117 30,803 55,090 <BR> --------------------------------------------------------------------------------------------------------------------------------------- <BR> Total 47,183 43,086 43,066 90,270 85,495 1,64,129 <BR> =================================================================== <BR> <BR> 5) The Consolidated Financial Results includes the Results of the following Companies <BR> <BR> Name of the Company % shareholding Consolidated as <BR> <BR> Xtend Industrial Designers & Engineers Pvt. Ltd. 100 Subsidiary <BR> Indoco Remedies Czech S R O 100 Subsidiary <BR> Indoco Remedies UK Ltd. 100 Subsidiary <BR> Warren Remedies Private Limited 100 Subsidiary <BR> FPP Holding Company, LLC 85 Subsidiary <BR> ----------------------------------------------------------------------------------------------------------- <BR> 6)The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th September, 2025. <BR> 7) (*) Exceptional items includes : (a) Consideration received Rs. 160 lakhs for grant to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company, and, (b) Loss amounting to Rs. 213 lakhs on sale and leaseback of its Non current Assets. <BR> <BR> 2025-04-012025-09-30UnauditedConsolidated92435000002390000092674000002185100000780500000-162500000210250000050680000061950000037320000009763900000-496500000-5300000-501800000500000-46800000-463000000-4555000000000-45550000024300000-431200000-437100000-18400000-412800000-184000001845000002-4.94-4.9400-4.94-4.94RESEARCH & DEVELOPMENT EXPENSES218100000OTHER EXPENSES1712400000RESEARCH & DEVELOPMENT EXPENSES434700000OTHER EXPENSES329730000094865000001816800000021520000011406000005909000000014600000035900000594000001099000009072000001426710000042464000000452620000012660000066600000349000003830000047926000002184000001555700000108131000002508020000018450000096132000009797700000-5460000097431000004940500000318000004972300000347100000923000007490000054866000005046600000855900000197270000028286000001041900000891710000050130000043210000098505000001533710000025080200000506800000-52800000-10463000000318900000-229000001960000048000000744000000026980000006195000000-19400000-2640000026670000048160000033800000059000009000000000101000003500000021144000001612600000000348000000157780000000000000452800000103740000000000000000000000059000000-16900000-595600000000000000400600000412000001840000051650000000-976700000550000005500000121100000126600000Items that will not be reclassified to profit and loss-7700000-7700000Items that will not be reclassified to profit and loss-15300000-15300000-1900000-3800000Items that may be reclassified to profit & loss3650000036500000Items that may be reclassified to profit & loss4520000045200000490000094000002580000024300000